EyePoint Pharmaceuticals, Inc. (EYPT)
Automate Your Wheel Strategy on EYPT
With Tiblio's Option Bot, you can configure your own wheel strategy including EYPT - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol EYPT
- Rev/Share 0.8033
- Book/Share 4.277
- PB 1.9687
- Debt/Equity 0.0807
- CurrentRatio 7.8456
- ROIC -0.5004
- MktCap 579394514.0
- FreeCF/Share -2.1688
- PFCF -3.8292
- PE -4.0021
- Debt/Assets 0.0664
- DivYield 0
- ROE -0.5427
- Rating C
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 1
- P/B Score 4
- D/E Score 3
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Initiation | EYPT | RBC Capital Mkts | -- | Outperform | -- | $28 | June 17, 2025 |
| Initiation | EYPT | Citigroup | -- | Buy | -- | $33 | Jan. 7, 2025 |
| Initiation | EYPT | Scotiabank | -- | Sector Outperform | -- | -- | Oct. 16, 2024 |
| Initiation | EYPT | Jefferies | -- | Buy | -- | $15 | Aug. 28, 2024 |
News
EyePoint Stock: Retaining My 'Risky Buy' Call - Pivotal Data Due Early 2026
Published: June 12, 2025 by: Seeking Alpha
Sentiment: Neutral
EyePoint Pharmaceuticals, Inc.'s Duravyu shows promising Phase 2 results in DME, supporting a slightly risky 'Buy' call ahead of pivotal Phase 3 readouts in 2026. Duravyu's potential for less frequent dosing could offer a key advantage over current market leaders Eylea and Vabysmo. Rapid enrollment in Phase 3 trials and robust safety/efficacy data boost confidence, but competition and market fragmentation remain significant risks.
Read More
Breakout Momentum Plays You May Not Know About
Published: June 06, 2025 by: MarketBeat
Sentiment: Neutral
High volatility has plagued markets throughout much of 2025. While many consider this a bad thing, particularly when trends point downward, it can also create opportunities for momentum investors to capture gains when target stocks are up.
Read More
EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Published: May 16, 2025 by: GlobeNewsWire
Sentiment: Neutral
WATERTOWN, Mass., May 16, 2025 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (Nasdaq: EYPT), a company committed to developing and commercializing therapeutics to help improve the lives of patients with serious retinal diseases, today announced that the Company granted non-statutory stock options to new employees as inducement awards outside the Company's 2023 Long-Term Incentive Plan in accordance with NASDAQ Listing Rule 5635(c)(4).
Read More
EyePoint Pharmaceuticals, Inc. (EYPT) Q1 2025 Earnings Call Transcript
Published: May 07, 2025 by: Seeking Alpha
Sentiment: Neutral
EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT ) Q1 2025 Earnings Conference Call May 7, 2025 8:30 AM ET Company Participants George Elston - Executive Vice President & Chief Financial Officer Jay Duker - President & Chief Executive Officer Ramiro Ribeiro - Chief Medical Officer Conference Call Participants Jennifer Kim - Cantor Tessa Romero - JPMorgan Tyler Van Buren - TD Cowen Yatin Suneja - Guggenheim Kambiz Yazdi - Jefferies Nick Quartapella - Baird Deb Chatterjee - Jones Yale Jen - Laidlaw & Company Yigal Nochomovitz - Citigroup Operator Good morning. My name is Towanda and I will be your conference operator today.
Read More
EyePoint Pharmaceuticals (EYPT) Reports Q1 Earnings: What Key Metrics Have to Say
Published: May 07, 2025 by: Zacks Investment Research
Sentiment: Positive
The headline numbers for EyePoint Pharmaceuticals (EYPT) give insight into how the company performed in the quarter ended March 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Read More
EyePoint Pharmaceuticals (EYPT) Reports Q1 Loss, Tops Revenue Estimates
Published: May 07, 2025 by: Zacks Investment Research
Sentiment: Neutral
EyePoint Pharmaceuticals (EYPT) came out with a quarterly loss of $0.65 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.55 per share a year ago.
Read More
EyePoint to Report First Quarter 2025 Financial Results on May 7, 2025
Published: April 30, 2025 by: GlobeNewsWire
Sentiment: Neutral
WATERTOWN, Mass., April 30, 2025 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal diseases, today announced it will host a conference call and live webcast at 8:30 a.m. ET on Wednesday, May 7, 2025 to report its first quarter 2025 financial results and highlight recent corporate developments.
Read More
EyePoint to Present at 2025 RBC Capital Markets Ophthalmology Virtual Conference
Published: March 27, 2025 by: GlobeNewsWire
Sentiment: Neutral
WATERTOWN, Mass., March 27, 2025 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal diseases, today announced that Jay S. Duker, M.D., President and Chief Executive Officer of EyePoint, will participate in a fireside chat at the 2025 RBC Capital Markets Ophthalmology Conference on Friday, April 4, 2025 at 10:00 a.m. ET.
Read More
EyePoint Pharmaceuticals, Inc. (EYPT) Q4 2024 Earnings Call Transcript
Published: March 05, 2025 by: Seeking Alpha
Sentiment: Neutral
EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT ) Q4 2024 Earnings Conference Call March 5, 2025 8:30 AM ET Company Participants George Elston - EVP and CFO Jay Duker - President and CEO Ramiro Ribeiro - Chief Medical Officer Conference Call Participants Tessa Romero - JPMorgan Yigal Nochomovitz - Citigroup Yatin Suneja - Guggenheim Kambiz Yazdi - Jefferies Jennifer Kim - Cantor Fitzgerald Graig Suvannavejh - Mizuho Securities Colleen Kusy - Baird Debanjana Chatterjee - JonesTrading Gregory Harrison - Scotiabank Yale Jen - Laidlaw & Company Yi Chen - H.C. Wainwright Operator Good morning.
Read More
EyePoint Pharmaceuticals (EYPT) Reports Q4 Loss, Lags Revenue Estimates
Published: March 05, 2025 by: Zacks Investment Research
Sentiment: Negative
EyePoint Pharmaceuticals (EYPT) came out with a quarterly loss of $0.64 per share versus the Zacks Consensus Estimate of a loss of $0.41. This compares to loss of $0.33 per share a year ago.
Read More
EyePoint to Report Fourth Quarter and Full-Year 2024 Financial Results on March 5, 2025
Published: February 26, 2025 by: GlobeNewsWire
Sentiment: Neutral
WATERTOWN, Mass., Feb. 26, 2025 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal diseases, today announced it will host a conference call and live webcast at 8:30 a.m.
Read More
EyePoint to Present Corporate Update at TD Cowen 45th Annual Health Care Conference
Published: February 25, 2025 by: GlobeNewsWire
Sentiment: Neutral
– Company presentation scheduled on Tuesday, March 4 th at 9:10am ET – – EyePoint to provide enrollment update for ongoing DURAVYU™ Phase 3 pivotal program in wet AMD and additional subgroup analyses from Phase 2 VERONA clinical trial in DME – WATERTOWN, Mass., Feb. 25, 2025 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal diseases, today announced that Jay S.
Read More
EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Published: February 17, 2025 by: GlobeNewsWire
Sentiment: Neutral
WATERTOWN, Mass., Feb. 17, 2025 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing therapeutics to help improve the lives of patients with serious retinal diseases, today announced that the Company granted non-statutory stock options to new employees as inducement awards outside the Company's 2023 Long-Term Incentive Plan in accordance with NASDAQ Listing Rule 5635(c)(4).
Read More
About EyePoint Pharmaceuticals, Inc. (EYPT)
- IPO Date 2005-01-27
- Website https://eyepointpharma.com
- Industry Biotechnology
- CEO Dr. Jay S. Duker M.D.
- Employees 165